alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Postal Service

# AGENCY:

                        Postal Service TM.                    

# ACTION:

Notice.

# SUMMARY:

The Postal Service gives notice of filing a request with the Postal Regulatory Commission to add a domestic shipping services contract to the list of Negotiated Service Agreements in the Mail Classification Schedule's Competitive Products List.

# DATES:

*Date of required notice:*                         September 19, 2024.                    

# FOR FURTHER INFORMATION CONTACT:

Sean C. Robinson, 202-268-8405.

# SUPPLEMENTARY INFORMATION:

                    The United States Postal Service ® hereby gives notice that, pursuant to 39 U.S.C. 3642 and 3632(b)(3), on September 10, 2024, it filed with the Postal Regulatory Commission a                     *USPS Request to Add Priority Mail Express, Priority Mail & USPS Ground Advantage ® Contract 317 to Competitive Product List.*                     Documents are available at                     *www.prc.gov*, Docket Nos. MC2024-650, CP2024-659.                

Sean C. Robinson,

Attorney, Corporate and Postal Business Law.

[FR Doc. 2024-21345 Filed 9-18-24; 8:45 am]

BILLING CODE 7710-12-P
# C_2022163EN.01000401.xml

| 19.4.2022 | EN | Official Journal of the European Union | C 163/4 |
| --- | --- | --- | --- |

19.4.2022

EN

Official Journal of the European Union

C 163/4

---

Summary of European Commission Decisions on authorisations for the placing on the market for the use and/or for use of substances listed in Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)

(Published pursuant to Article 64(9) of Regulation (EC) No 1907/2006 (1))

(Text with EEA relevance)

(2022/C 163/04)

Decision granting an authorisation

| Reference of the decision (2) | Date of decision | Substance name | Holder of the authorisation | Authorisation number | Authorised use | Date of expiry of review period | Reasons for the decision |
| --- | --- | --- | --- | --- | --- | --- | --- |
| C(2022) 2178 | 11 April 2022 | 4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated
  (4-tert-OPnEO)
  EC No: -, CAS No:- | DIAGAST, Parc Eurasante 251, avenue Eugène Avinée, 59120 Loos, France | REACH/22/21/0 | Industrial use of 4-tert-OPnEO for its amphiphilic, surfactant and non-haemolytic properties to create controlled hydrophilic spots on porous hydrophobic membranes (solid form) for in vitro diagnostic kits for blood testing via antigen or antibody reaction in the following product range: control cards, manual pads and automated ONYX | 4 January 2033 | In accordance with Article 60(4) of Regulation (EC) No 1907/2006, the socio-economic benefits outweigh the risk to human health and the environment from the use of the substance and there are no suitable alternative substances or technologies. |

Reference of the decision (2)

Date of decision

Substance name

Holder of the authorisation

Authorisation number

Authorised use

Date of expiry of review period

Reasons for the decision

C(2022) 2178

11 April 2022

4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated

(4-tert-OPnEO)

EC No: -, CAS No:-

DIAGAST, Parc Eurasante 251, avenue Eugène Avinée, 59120 Loos, France

REACH/22/21/0

Industrial use of 4-tert-OPnEO for its amphiphilic, surfactant and non-haemolytic properties to create controlled hydrophilic spots on porous hydrophobic membranes (solid form) for in vitro diagnostic kits for blood testing via antigen or antibody reaction in the following product range: control cards, manual pads and automated ONYX

4 January 2033

In accordance with Article 60(4) of Regulation (EC) No 1907/2006, the socio-economic benefits outweigh the risk to human health and the environment from the use of the substance and there are no suitable alternative substances or technologies.

---

(1)  OJ L 396, 30.12.2006, p. 1.

(2)  The decision is available on the European Commission website at: Authorisation (europa.eu).

---
<PAGE>   1
 
                                                                      EXHIBIT 12
 
                  OUTBOARD MARINE CORPORATION AND SUBSIDIARIES
 
            COMPUTATION OF RATIO OF EARNINGS (LOSS) TO FIXED CHARGES
 
<TABLE>
<CAPTION>
                                                           YEARS ENDED SEPTEMBER 30,
                                               -------------------------------------------------
                                               POST-MERGER
                                                 COMPANY              PRE-MERGER COMPANY
                                               -----------    ----------------------------------
                                                  1998         1997      1996     1995     1994
                                               -----------    ------    ------    -----    -----
                                                          (IN MILLIONS EXCEPT RATIOS)
<S>                                            <C>            <C>       <C>       <C>      <C>
Earnings (loss):
  Earnings (loss) before provision for income
     taxes...................................    $(147.1)     $(76.3)   $(10.4)   $60.8    $53.4
  Interest expense...........................       30.1        16.2      12.3     23.1     15.1
  Interest portion of rent expense...........        1.2         1.1       1.2      1.3      1.3
                                                 -------      ------    ------    -----    -----
     Earnings (loss).........................    $(115.8)     $(59.0)   $  3.1    $85.2    $69.8
                                                 -------      ------    ------    -----    -----
Fixed Charges:
  Interest expense...........................       30.1        16.2      12.3     23.1     15.1
  Interest portion of rent expense...........        1.2         1.1       1.2      1.3      1.3
                                                 -------      ------    ------    -----    -----
     Fixed Charges...........................    $  31.3      $ 17.3    $ 13.5    $24.4    $16.4
                                                 =======      ======    ======    =====    =====
Ratio of earnings to fixed charges...........                                       3.5      4.3
                                                                                  =====    =====
Excess of fixed charges over earnings........    $ 147.1      $ 76.3    $ 10.4
                                                 =======      ======    ======
</TABLE>
<PAGE> 1

Letter Re:  Unaudited Interim Financial Information
___________________________________________________

Aetna Inc.
Hartford, Connecticut

Gentlemen:

Re:  Registration Statements No. 33-52819, 33-52819-01, 333-
07167, 
333-07169, 333-08427, 333-08429 and 333-08431


With respect to the subject registration statements, we 
acknowledge our awareness of the use therein of our report 
dated October 23, 1996 related to our review of interim 
financial information.

Pursuant to Rule 436(c) under the Securities Act of 1933, 
such report is not considered a part of a registration 
statement prepared or certified by an accountant or a report 
prepared or certified by an accountant within the meaning of 
Sections 7 and 11 of the Act.




                             By   /s/  KPMG PEAT MARWICK LLP 
                                ____________________________
                                         (Signature)
                                 KPMG Peat Marwick LLP

Hartford, Connecticut
October 23, 1996
FERRETERIA E IMPLEMENTOS SAN FRANCISCO 

211 ESPERANZA 

July 28, 2013 

U.S. Department of Transportation 

Document Management System 

400 ih Street SW. Room PL 401 

Washington D.C. 20591-0001 

LAREDO, TX 78041 

Petitioner: Ferreteria E lmplementos San Francisco FEIB860D, a part 125 certificate holder. 

211 Esperanza, Laredo TX 78041 

Ferreteria E lmplementos San Francisco, the petitioner is requesting relief from FAR 125 .224a. 

Requiring the installation ofTCAS equipment meeting TSO C-119. 

Petitioner is requesting relief from FAR 125.224a and in lieu requests authority to comply with 

125.224b. for a specific aircraft. The aircraft in question is N173RV, Nihon YS-11. We removed this 

aircraft from operation when the TCAS requirement was required. There is no STC available for this 

aircraft meeting C-119, but we know of one other YS-11 equipped with a system meeting TSO C-118. 

The Nihon YS-11 is a relative slow aircraft operating in the same performance range and lift category as 

another aircraft operated by petitioner, a Convair 440. The Convair, being piston powered utilizes TCAS 

meeting C-118. Our experience with this similar aircraft has shown the C-118 equipment adequate. 

Petitioner is of the opinion that in view of the scope and nature of it's' operations, there is no benefit to 

public safety by the installation of the enhanced TCAS in this particular aircraft. The utilization of our 

aircraft is in the limited range of three hundred flight hours annually per aircraft. Additionally we are 

freight only, and seldom use passenger hub type airports. The benefits envisioned by the regulation is 

predicated on the performance of a class of aircraft although defined by weight, is really about speed 

and climb rate which this aircraft lacks. This circumstance negates the advantages, but magnifies the 

economic burden on the operator. 

The petitioner maintains authority to operate in Mexico and is subject to verification of Operating 

Specifications and deviations by the civil authority of that nation. Petitioner will be required to submit 

any relief granted to the Mexico authorities. 

Sincerely, 0 

Douglas R. Taylor, diG!rop~
DRAFTCOPYPage1of1UnitedStatesEnvironmentalProtectionOMBApproval2070-174AgencyWashington,D.C.20460REQUIREMENTSSTATUSANDREGISTRANT'SRESPONSEINSTRUCTIONS:Pleasetypeorprintinink.Pleasereadcarefullytheattachedinstructionsandsupplytheinformationrequestedonthisform.Useadditionalsheet(s)ifnecessary.1.CompanyNameandAddress2.Case#andName3.DateandTypeofDCIandNumberSAMPLECOMPANYNOSTREETADDRESSNOCITY,XX00000Chemical#andNameFlumetsulam4.GuidelineRequirementNumber830.7050870.6200870.78005.StudyTitleProductChemistryDataRequirements(ConventionalChemical!UVNisibleabsorptionToxicologyDataRequirements(ConventionalChemical)Neurotoxicityscreeningbattery(1,2)lmmunotoxicity129016pRProgressReports0gt--r---,.....--1L1 23NNN6.UsePatternA,BA,BA,BDD-MMM-YYYYGENERICID#GDCI-129016-NNNNN7.TestSubstancePAI;TGAITGAITGAI8.TimeFrame(Months)8241210.CertificationIcertifythatthestatementsmadeonthisformandallattachmentsaretrue,accurate,andcomplete.Iacknowledgethatany11.Dateknowinglyfalseormisleadingstatementmaybepunishablebyfine,imprisonmentorbothunderapplicablelawSignatureandTitleofCompany'sAuthorizedRepresentative12.NameofCompany13.PhoneNumber9.RegistrantResponseDRAFT COP

Y

United States Environmental Protection Age

n cy Washington

, D. C

. 20460 FOOTNOTES
AND KEY DEFINITIONS

FOR GUIDELINE REQUIREMENTS Case

# and Name: DCI
N u mber: GDCI-129016-NNNNN Key:
PA

l ; TGA

I =Pure Active ingredient

, Technical Grade

of the Active Ingredient; TGAI

= Tech nica

l Grade Active Ingred ient [TGAI) U se Categories

Key

: A

- Terrestr

i al food crop 8 - Terrestrial feed crop Footnotes:

[The following notes are referenced

I n column two
(5

. Study File) of the REQUIREMENTS STATUS AND REG
IS TRANT

'S RESPONSE form.) 1 90-day Neurotox icity

- rat: 2

As determined

by the Agency, additional measurements

may also be required, such as cholinesterase

act

i v ity for certain pesticides,

e

. g ., organophosphates

and some carbamates

. The route
of exposure must correspond
with the primary route
of exposure

. All 90-day subchronic studies

in rats can be designed

to simultaneously

fulfill the requirements

of the 90-day neurotoxicity study
us

i ng separate groups

of animals

for testing

. Although

the subchronic

gu

i del

i nes include the measurement

of neuro

l og

i cal endpo

i nts

, they do not meet the requ

i rement

of the 90-day neurotox

i c

i ty study

. Acute neurotoxicity

- rat: As determined

by the Agency

, additional measurements

may also be required

, such as cholinesterase activity
for certain pesticides

, e.g.

, organophosphates

and some carbamates

. The route
of exposure must correspond
with the primary route
of exposure

.

Page

1 of
1
UNITE D STATE S ENVIRONMENTA L PROTECTIO N AGENC Y SFgN D RECORD S CT R REGIO N I X2201-9015 2 7 5 Hawthorn e Stree t Sa n Francisco , Ca . 94105-390 1 SFUN D RECORD S CT R 

### 8815186 0 MEMORANDUM DATE : Octobe r 4 , 199 3 SUBJECT : R

ARepor t fo r Sol a Optica l FROM : Nanc yLindsa y~~ } TO : Fil e On Augus t 14 , 1992 , the Regiona l Administrato r signed an "InterimClos e Ou t Report " fo r Sol a Optical , indicating tha t th e construction o f th e remedia l actio n wa s complet e and operational . (Accordin

g t o curren t guidance , thi s repor t todaywoul d b e calle d a PreliminaryClos e Ou t Report. ) Sinc e Sol a Optica l ha s onl yon e operabl e unit , th e constructio

n completio n fo r the operabl e uni t coincide d wit hthe construction completio n o f the entir e site . Th e purpos e o f thi s mem o i s t o documen t fo r th e fil e tha t th e "Interi mClos e Ou t Report " serve s t o documen t th e constructio n completio n o f th e operabl e uni t a s wel l a s th e entir e site . Th e nee d fo r thi s clarificatio n aros e du e t o an I GAudi t o f Regio n I X accomplishments . Sinc e thi s accomplishmen t i s mor e than a yea r past , th e I Gagree d t o allo wth e "Interi mClos e Ou t Report " and thi s mem o t o suffic e fo r th e R ARepor t a t Sol a Optical . I n the future , Regio n I X i s committe d t o writing an R A Repor t t o documen t th e R AComplet e accomplishmen t fo r al l sites .

Printed on Recycled

Paper
|   | (1) | The      Report fully complies with the requirements of Section 13(a) or 15(d)      of the Securities Exchange Act of 1934;and |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | The      information contained in the Report fairly presents, in all material      respects, the financial condition and results of operations of the      Company. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| /s/ Tod      A. Nestor                                 |   |
|--------------------------------------------------------|--------|
| Tod      A. Nestor                                     |   |
| Senior      Vice President and Chief Financial Officer |   |
|                                                   |   |
| April 21,      2009                                    |   |

----
xml version="1.0" encoding="UTF-8"?


C\_2022356EN.01000401.xml


| | | | |
| --- | --- | --- | --- |
| 16.9.2022 | EN | Official Journal of the European Union | C 356/4 |

---

Prior notification of a concentration

(Case M.10889 – CNP / CVA)

Candidate case for simplified procedure

(Text with EEA relevance)

(2022/C 356/04)

1.

On 9 September 2022, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 [(1)](#ntr1-C_2022356EN.01000401-E0001).

This notification concerns the following undertakings:

| | |
| --- | --- |
| — | CNP Assurances S.A. (‘CNP’, France), controlled by Caisse des Dépôts et Consignations (‘CDC’, France), |

| | |
| --- | --- |
| — | CNP Vita Assicura S.p.A. (‘CVA’, Italy), jointly controlled by CNP and UniCredit S.p.A. (‘UniCredit’, Italy). |

CNP will acquire within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of CVA.

The concentration is accomplished by way of purchase of shares.

2.

The business activities of the undertakings concerned are the following:

| | |
| --- | --- |
| — | CNP develops, provides and manages insurance products globally. In Italy, CNP is mainly active in the provision of life insurance products, |

| | |
| --- | --- |
| — | CVA is an insurance company currently jointly controlled by CNP and UniCredit that provides life insurance products in Italy. |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 [(2)](#ntr2-C_2022356EN.01000401-E0002) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.10889 – CNP / CVA

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

| |
| --- |
| European Commission |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

---

[(1)](#ntc1-C_2022356EN.01000401-E0001)  [OJ L 24, 29.1.2004, p. 1](http://publications.europa.eu/resource/oj/JOL_2004_024_R_TOC) (the ‘Merger Regulation’).

[(2)](#ntc2-C_2022356EN.01000401-E0002)  [OJ C 366, 14.12.2013, p. 5](http://publications.europa.eu/resource/oj/JOC_2013_366_R_TOC).

---
Supplemental Long Term Disability Plan



  
 Exhibit 10.78

  
 POLICY 
 Supplemental Long Term Disability Plan 
 Page 1 of 2 

 
 STATEMENT 
  
 Invitrogen Corporation offers Supplemental Long Term Disability (LTD) benefits to provide top executives with a level of coverage comparable
to that provided to all other employees. The plan works in conjunction with the Company sponsored group LTD plan to provide salary continuation in excess of limits in the LTD group plan. The goal of the plan is to ensure financial stability in the
event of disability. 
  
 ELIGIBILITY 
  
 You are eligible for benefits if you are classified in the Executive Leadership Career Band
as of January 1, 2004. Coverage is effective on April 1, 2004 subject to timely completion and return of a UnumProvident enrollment form. Employees joining the eligible group after the initial enrollment will be eligible for coverage on the first of
the month following the effective date of joining the eligible group. Coverage is available for employee only. 
  
 PLAN BENEFITS 
  
 Supplemental LTD
provides for salary continuation in the event you are disabled for more than six months (180 days). Salary continuation is payable at a rate of 75% of your base monthly salary in excess of the plan limit in the Invitrogen group LTD Plan. The maximum
benefit payable under this plan is $15,000 per month. You must complete and submit an enrollment form to be covered under the plan. In order to be considered for maximum coverage, you will be required to submit to a medical exam as prescribed by
UnumProvident. If you do not submit to a medical exam, or if you are unable to meet the medical requirements of the exam, coverage will be limited to a maximum benefit of $3,000 per month. 
  
 Benefits are payable for the duration of your disability or until you reach age 65, whichever
comes first. You must be medically disabled from performing the duties of your own occupation to qualify for benefits. Disability must be certified by a licensed physician in accordance with plan provisions.  
  
 COST 
  
 Invitrogen will pay the full cost of your coverage under this plan. Benefits payments you receive while disabled under this plan are taxable
when they are received. 
  
 PLAN ADMINISTRATION 
  
 The Supplemental LTD Plan is administered by Corporate Benefits through a fully insured
contract with Unum Life Insurance Company. If you have any questions regarding eligibility or benefits, please contact the Benefits Manager in the Carlsbad office for assistance at 1-760-476-6332. 
  









 POLICY 
 Supplemental Long Term Disability Plan 
 Page 2 of 2 
  
 AUTHORITY 
  
 Invitrogen has the authority to discontinue, change, modify, or approve exceptions to this policy at any time with or without notice. In the event of any difference
between plan information in this policy and the insurance contract, the contract will prevail.
T hi s di s pos i t i on i s notappr opr i a t e f orpubl i c a t i on and i s notpr e c e de nt * e xc e pta s pr ovi de d by9th C i r . R . 36- 3.

T he pa ne l una ni m ous l yc onc l ude s thi s c a s e i s s ui t abl e f orde c i s i on ** w ith o u t o r a l ar g u m e n t. See F ed. R . A pp . P . 34 (a )( 2). LR / R es ear ch NOT F OR P UB L I CAT I ON

UN I TE D STATE S C OU RT OF APPE ALS FOR T HE NI NTH CI RC UI T VERONI CA GA SGA SI ER RA; CI RI LO AN TONI O SI ER RA VA SQUEZ, P et i t i o n ers, v. E R I C H . H O L D E R J r ., A tto rn e yG e n e r a l, R e s p o n d e n t. N o. 07- 74375 A ge nc yN os . A 075- 476- 095

A 075- 475- 327 ME MOR AN DU M *

O n P e t i t i on f

orR e vi e w of

a n O r de rof

the B o a r do f I m m ig r a tio n A p p e a ls S ubm i tt e d J anua ry11, 2010 ** B efo re: B E E Z E R , T R O T T , an dB Y B E E , C i rcu i tJu d g es. V e r oni c aG a s gaS i e rr aa nd C i r i l o A nt oni o S i e rr aV a s que z , na t i ve s a nd ci t i zen s o f M ex i co , p et i t i o n fo r rev i ew o f th e B o ardo f Im m i g rat i o n A p p eal s’ ( “ B I A ” ) or de rde ny i ng the i rm ot i on t o r e ope n. W e ha ve j ur i s di c t i on pur s uantt o 8 

# FI LED JAN 21 2 010 M OLLY C. DW Y ER, CLERK U . S. C O U R T OF APPE ALSL R/ Res ea r ch 07- 74375 2 U . S . C . § 1252. W e r e vi e w f orabus e of

di s c r e t i on the de ni a l of am ot i on t o r e o p e n , Moh am m ed v. G on zales , 4 0 0 F . 3 d7 8 5 , 7 9 1 (9 th C i r. 2 0 0 5 ), an dw e d en y th e p e t i t i o n f

o rr e v i e w. T h e B IA ac tedw ith init s d iscr etio n ind en yin g as u n ti m ely p etit io n er s’ m ot i on t o reopen b ec ause i tw as fi l ed m ore than 9 0 d ay s a ft erthe B IA ’ s f i nal r e m o v a l o r d e r , se e 8 C . F . R . § 1 0 0 3 . 2 (c)(2 ), an dp et i t i o n ers d i dn o tsh o w th atth ey a c te dw ith th e du e d ilig e n c e r e q u ir e df o re q u itab le to llin g , s e e Si ngh v. G on zales , 4 9 1 F .3 d1 0 9 0 , 1 0 9 6 - 9 7 ( 9 th C ir . 2 0 0 7 ) . P E T I T I ON F OR RE V I E W DE NI E D.